HPS Pharmacies wish to give notice that Dr Reddy’s Laboratories, in consultation with the Therapeutic Goods Administration (TGA), has initiated a drug recall for Dasatinib Dr.Reddy’s tablets as follows:

Dasatinib Dr.Reddy’s Tablets
Dasatinib 70mg
ARTG 337456

The only batch affected by this drug recall is: ZH20022 (Exp: Dec 2023)

This drug recall was initiated following out of specification results for dissolution observed during stability testing. Failure in the dissolution test can result in incomplete release of the medicine and lack of efficacy.

There have been no reports of adverse events related to this issue.

Please inspect your stock and quarantine any defect stock. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined for return to the supplier, and HPS Pharmacies will arrange for replacement stock as soon as possible. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Dr Reddy’s Laboratories on 1800 274 276 or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates